Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T11:53:59.763Z Has data issue: false hasContentIssue false

Hospital-mandated restrictions during the COVID-19 pandemic alter hospital-acquired viral respiratory infections during hematopoietic stem cell transplantation: a single center pediatric experience

Published online by Cambridge University Press:  01 December 2025

Perry Morocco
Affiliation:
Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, IL, USA
Madan Kumar
Affiliation:
Department of Infectious Disease, Comer Children’s Hospital, University of Chicago, Chicago, IL, USA
Miranda Foote
Affiliation:
Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, IL, USA
Caitlin Cohen
Affiliation:
Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, IL, USA
Michelle Nassin
Affiliation:
Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, IL, USA
John Cunningham
Affiliation:
Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, IL, USA
James LaBelle*
Affiliation:
Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago, Chicago, IL, USA
*
Corresponding author: James LaBelle; Email: jlabelle@bsd.uchicago.edu

Abstract

Objective:

Evaluating the COVID-19 pandemic restrictions and their effect on rates of new respiratory viral infections in patients undergoing hematopoietic stem cell transplantation (HSCT), and if there were changes to the morbidity and mortality rates compared to historical controls.

Design:

Retrospective chart review.

Setting:

University-based tertiary care center.

Patients:

All patients who underwent HSCT, including chimeric antigen receptor T-cell therapy, between 7/1/2013 and 12/19/2021 were included in the study. No eligible patients were excluded.

Results:

We found a significant difference in new respiratory infections as measured by a respiratory viral pathogen (RVP) polymerase chain reaction-based assay during transplant admissions between the pre- and early COVID-19 eras, with complete absence of new respiratory viral infections in the early COVID-19 era. The late-COVID-19 era, coincident with availability of severe acute respiratory syndrome coronavirus 2 vaccines and relaxation of some hospital-based restrictions, had a similar incidence of new RVP positivity compared to the pre-COVID-19 era. For allogeneic HSCT outcomes alone, rates of pediatric intensive care unit admission (66.7% vs 32.2%, p = .01), intubation (57.1% and 18.6%, p < .01), and oxygen requirement (66.7% vs 40.7%, p = .04) were found to be statistically different with new RVP positivity. Other outcomes examined, including death at 100/180/365 days post-transplant, length of stay, and acute graft-versus-host disease incidence, were similar, regardless of new RVP positivity.

Conclusions:

In order to reduce morbidity, these findings argue for a continuation of the strict protective isolation practices initially employed during the pandemic for HSCT patients, particularly during viral emergence following the COVID-19 lockdown.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Patient characteristics for all transplant admissions

Figure 1

Table 2.Patients per analysis by era

Figure 2

Figure 1.Hospital-acquired respiratory viral pathogen (RVP) positivity in pediatric hematopoietic stem cell transplantation (HSCT) patients by era. The early COVID era demonstrated a complete absence of new RVP positivity, while the pre-COVID and late COVID eras had similar rates of RVP positivity.

Figure 3

Table 3.Autologous outcomes based on new RVP +

Figure 4

Table 4.Allogeneic outcomes based on new RVP +

Figure 5

Figure 2.Hospital-wide respiratory viral pathogen (RVP) data by era.

Figure 6

Figure 3.Respiratory pathogens identified in hematopoietic stem cell transplantation (HSCT) patients by era.